Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy

Nature Communications

Volumn 5, Issue , 2014, Pages

  Burton, Bronwen R ^a   Britton, Graham J ^a   Fang, Hai ^a   Verhagen, Johan ^a   Smithers, Ben ^a   Sabatos Peyton, Catherine A ^a   Carney, Laura J ^a   Gough, Julian ^a   Strobel, Stephan ^b   Wraith, David C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 2; MBP AC1 9[4Y]; MYELIN BASIC PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR C MAF; TRANSCRIPTION FACTOR NFIL3; UNCLASSIFIED DRUG; AUTOANTIGEN; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CD223 ANTIGEN; DRUG MIXTURE; FREUND ADJUVANT; HAVCR2 PROTEIN, MOUSE; IL10 PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; MAF PROTEIN, MOUSE; NFIL3 PROTEIN, MOUSE; PDCD1 PROTEIN, MOUSE; PEPTIDE; PROGRAMMED DEATH 1 RECEPTOR; T CELL IG AND ITIM DOMAIN PROTEIN, MOUSE; TRANSCRIPTOME; VIRUS RECEPTOR;

ANTIGEN; CORRELATION; GENE EXPRESSION; GENETIC ANALYSIS; IMMUNITY; IMMUNOASSAY; PATHOGEN;

ABNORMAL POSTURE; ANTIGEN SPECIFIC IMMUNOTHERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CELL CYCLE; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG TOLERANCE; DYSPNEA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUNCHED POSTURE; IMMUNOREGULATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; REFLEX; T LYMPHOCYTE ACTIVATION; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; CLONAL ANERGY; DESENSITIZATION; DRUG EFFECTS; DRUG MIXTURE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; PATHOLOGY; PROCEDURES; SPINAL CORD; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD; AUTOANTIGENS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CD4-POSITIVE T-LYMPHOCYTES; CLONAL ANERGY; COMPLEX MIXTURES; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FREUND'S ADJUVANT; GENE EXPRESSION REGULATION; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-10; MALE; MICE; MICE, TRANSGENIC; PEPTIDES; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS C-MAF; RECEPTORS, IMMUNOLOGIC; RECEPTORS, VIRUS; SPINAL CORD; TRANSCRIPTOME;

EID: 84907371316     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5741     Document Type: Article

References (58)

1. Sabatos-Peyton, C. A., Verhagen, J. & Wraith, D. C. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr. Opin. Immunol. 22, 609-615 (2010).
2. Miller, S. D., Turley, D. M. & Podojil, J. R. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat. Rev. Immunol. 7, 665-677 (2007).
3. Kang, H. K., Michaels, M. A., Berner, B. R. & Datta, S. K. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J. Immunol. 174, 3247-3255 (2005).
4. Satpute, S. R., Rajaiah, R., Polumuri, S. K. & Moudgil, K. D. Tolerization with Hsp65 induces protection against adjuvant-induced arthritis by modulating the antigen-directed interferon-gamma, interleukin-17, and antibody responses. Arthritis Rheum. 60, 103-113 (2009).
5. Matta, B., Jha, P., Bora, P. S. & Bora, N. S. Antigen-specific tolerance inhibits autoimmune uveitis in pre-sensitized animals by deletion and CD4+CD25+ T-regulatory cells. Immunol. Cell Biol. 88, 187-196 (2010).
6. Warren, K. G., Catz, I., Ferenczi, L. Z. & Krantz, M. J. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur. J. Neurol. 13, 887-895 (2006).
7. Koffeman, E. C. et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 60, 3207-3216 (2009).
8. Thrower, S. L. et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin. Exp. Immunol. 155, 156-165 (2009).
9. Varshney, P. et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J. Allergy Clin. Immunol. 127, 654-660 (2011).
10. Burks, A. W. et al. Oral immunotherapy for treatment of egg allergy in children. New Engl. J. Med. 367, 233-243 (2012).
11. Mobs, C. et al. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies. J. Allergy Clin. Immunol. 130, 1108-1116.e6 (2012).
12. Campbell, J. D. et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J. Exp. Med. 206, 1535-1547 (2009).
13. Fousteri, G. et al. Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetologia 53, 1958-1970 (2010).
14. Tarzi, M. et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin. Exp. Allergy 36, 465-474 (2006).
15. Liu, G. Y. et al. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3, 407-415 (1995).
16. Burkhart, C., Liu, G. Y., Anderton, S. M., Metzler, B. & Wraith, D. C. Peptideinduced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int. Immunol. 11, 1625-1634 (1999).
17. Gabrysova, L. & Wraith, D. C. Antigenic strength controls the generation of antigen-specific IL-10-secreting T regulatory cells. Eur. J. Immunol. 40, 1386-1395 (2010).
18. Sundstedt, A., O'Neill, E. J., Nicolson, K. S. & Wraith, D. C. Role for IL-10 in suppression mediated by Peptide-induced regulatory T cells in vivo. J. Immunol. 170, 1240-1248 (2003).
19. Nicolson, K. S. et al. Antigen-induced IL-10+ regulatory T cells are independent of CD25+ regulatory cells for their growth, differentiation, and function. J. Immunol. 176, 5329-5337 (2006).
20. Anderson, P. O. et al. Persistent antigenic stimulation alters the transcription program in T cells, resulting in antigen-specific tolerance. Eur. J. Immunol. 36, 1374-1385 (2006).
21. Gabrysova, L. et al. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J. Exp. Med. 206, 1755-1767 (2009).
22. Burks, A. W. et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J. Allergy Clin. Immunol. 131, 1288-1296.e3 (2013).
23. Larche, M. & Wraith, D. C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11, S69-S76 (2005).
24. Liu, G. Y. & Wraith, D. C. Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice - implications for autoimmunity. Int. Immunol. 7, 1255-1263 (1995).
25. Pedotti, R. et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol. 2, 216-222 (2001).
26. Smith, C. E., Eagar, T. N., Strominger, J. L. & Miller, S. D. Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 102, 9595-9600 (2005).
27. Saraiva, M. et al. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31, 209-219 (2009).
28. Freitas do Rosario, A. P. et al. IL-27 promotes IL-10 production by effector Th1 CD4+ T cells: a critical mechanism for protection from severe immunopathology during malaria infection. J. Immunol. 188, 1178-1190 (2012).
29. Akdis, C. A., Blesken, T., Akdis, M., Wuthrich, B. & Blaser, K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest. 102, 98-106 (1998).
30. Meiler, F. et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med. 205, 2887-2898 (2008).
31. Fang, H. et al. Transcriptome analysis of early organogenesis in human embryos. Dev. Cell 19, 174-184 (2010).
32. Xiao, L., Wang, K., Teng, Y. & Zhang, J. Component plane presentation integrated self-organizing map for microarray data analysis. FEBS Lett. 538, 117-124 (2003).
33. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25-29 (2000).
34. Eppig, J. T., Blake, J. A., Bult, C. J., Kadin, J. A. & Richardson, J. E. The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse. Nucleic Acids Res. 40, D881-D886 (2012).
35. Matthews, L. et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 37, D619-D622 (2009).
36. Schriml, L. M. et al. Disease ontology: a backbone for disease semantic integration. Nucleic Acids Res. 40, D940-D946 (2012).
37. Hutloff, A. et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397, 263-266 (1999).
38. Pot, C. et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 183, 797-801 (2009).
39. Motomura, Y. et al. The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells. Nat. Immunol. 12, 450-459 (2011).
40. Apetoh, L. et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 11, 854-861 (2010).
41. Song, J., Salek-Ardakani, S., So, T. & Croft, M. The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat. Immunol. 8, 64-73 (2007).
42. Jackson, S. K., DeLoose, A. & Gilbert, K. M. Induction of anergy in Th1 cells associated with increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. J. Immunol. 166, 952-958 (2001).
43. Kamanaka, M. et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity 25, 941-952 (2006).
44. Gagliani, N. et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat. Med. 19, 739-746 (2013).
45. Harrison, L. C. & Hafler, D. A. Antigen-specific therapy for autoimmune disease. Curr. Opin. Immunol. 12, 704-711 (2000).
46. Chatenoud, L. et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49, 697-702 (1990).
47. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New Engl. J. Med. 355, 1018-1028 (2006).
48. Garber, K. Immunology: a tolerant approach. Nature 507, 418-420 (2014).
49. Noon, L. Prophylactic innoculation against hay fever. Lancet 1572-1573 (1911).
50. Zhang, J. a. F., H. in Applications of Self-Organizing Maps (ed. Johnsson, M.) 181-204 (In Tech, 2012).
51. Ng, T. H. et al. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 4, 129 (2013).
52. Hoyne, G. F., Askonas, B. A., Hetzel, C., Thomas, W. R. & Lamb, J. R. Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo. Int. Immunol. 8, 335-342 (1996).
53. Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492-499 (2011).
54. Okamura, T. et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc. Natl Acad. Sci. USA 106, 13974-13979 (2009).
55. Trinchieri, G. Interleukin-10 production by effector T cells: Th1 cells show self control. J. Exp. Med. 204, 239-243 (2007).
56. O'Garra, A. & Vieira, P. T(H)1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7, 425-428 (2007).
57. Verhagen, J. et al. Modification of the FoxP3 transcription factor principally affects inducible T regulatory cells in a model of experimental autoimmune encephalomyelitis. PLoS ONE 8, e61334 (2013).
58. Pavlidis, P. & Noble, W. S. Matrix2png: a utility for visualizing matrix data. Bioinformatics 19, 295-296 (2003).